Hypera S.A. (OTCMKTS:HYPMY – Get Rating)'s stock price hit a new 52-week high during trading on Wednesday . The stock traded as high as $9.33 and last traded at $9.22, with a volume of 112502 shares trading hands. The stock had previously closed at $9.08.

Wall Street Analysts Forecast Growth

Separately, The Goldman Sachs Group upgraded shares of Hypera from a "neutral" rating to a "buy" rating in a research report on Monday.

Hypera Trading Up 1.5 %

The firm has a 50-day moving average of $8.42 and a two-hundred day moving average of $7.96.

About Hypera

Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, MaxSulid, milgamma, Mioflex – A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.

Read More

• Get a free copy of the StockNews.com research report on Hypera (HYPMY)
• Is Netflix A Blockbuster Or Another Blockbuster Video?
• Intel – Are We Near A Bottom?
• Merck Nears Breakout Point After October Surprise Good News
• Target Is About To Start A 20% Rally Into The Holidays
• Does J&J Have Enough Alpha to Be a Solid Low Beta Stock?

Receive News & Ratings for Hypera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hypera and related companies with MarketBeat.com's FREE daily email newsletter.